Drug Type Small molecule drug |
Synonyms GST HG141, GST-HG141 |
Mechanism HBV core protein modulators, cccDNA inhibitors(cccDNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 2 | CN | 17 Jan 2023 | |
Viremia | Phase 2 | CN | 23 Nov 2022 |
Phase 1 | - | pgqudlmkug(cafvqozmqo) = ssvozsqfvd rzshnapjwb (gzdmcuiwwv ) | Positive | 25 Jun 2022 | |||
pgqudlmkug(cafvqozmqo) = zskujvzpmr rzshnapjwb (gzdmcuiwwv ) | |||||||
Phase 1 | - | vpdfipyinf(yacoujjcqc) = rxlopumkzz rnztxlnqxk (wvxwnbquqc, 3.65) View more | - | 23 Jun 2021 |